Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423
  1. Home
  3. A Review Of The Clinical Efficacy And Adverse Effects Of Disease Modifying Osteoarthritic Drugs (dmoads) In Dogs With Special Focus On Glucosamine And Pentosan Polysulfate; Do They Work?
  1. Home
  3. A Review Of The Clinical Efficacy And Adverse Effects Of Disease Modifying Osteoarthritic Drugs (dmoads) In Dogs With Special Focus On Glucosamine And Pentosan Polysulfate; Do They Work?

Related Experiment Video

Micro-Computed Tomography Analysis of the Knee in Aged Dunkin-Hartley Guinea Pigs after Intra Articular Injection
07:10

Micro-Computed Tomography Analysis of the Knee in Aged Dunkin-Hartley Guinea Pigs after Intra Articular Injection

Published on: August 2, 2024

726

A review of the clinical efficacy and adverse effects of disease modifying osteoarthritic drugs (DMOADs) in dogs with

Eugene C Bwalya1, Suranji Hm Wijekoon2, Masahiro Okumura3

  • 1Department of Clinical Studies, School of Veterinary Medicine, University of Zambia, Great East Road Main Campus, Lusaka, Zambia.

The Journal of Veterinary Medical Science
|November 3, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
disease modifying osteoarthritic drugeffect sizeglucosamineosteoarthritispentosan polysulfate

More Related Videos

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.7K
Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

11.9K

Related Experiment Videos

Micro-Computed Tomography Analysis of the Knee in Aged Dunkin-Hartley Guinea Pigs after Intra Articular Injection
07:10

Micro-Computed Tomography Analysis of the Knee in Aged Dunkin-Hartley Guinea Pigs after Intra Articular Injection

Published on: August 2, 2024

726
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.7K
Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

11.9K

This review examines disease-modifying osteoarthritis drugs (DMOADs), focusing on glucosamine and pentosan polysulfate. It evaluates their clinical efficacy and safety for osteoarthritis treatment.

Area of Science:

  • Rheumatology and Orthopedics
  • Pharmacology

Background:

  • Osteoarthritis (OA), also known as degenerative joint disease (DJD), is a prevalent and costly arthritis form.
  • Current treatments like NSAIDs manage symptoms but do not halt OA's structural joint degradation.
  • Disease-modifying osteoarthritis drugs (DMOADs) are emerging to target OA's underlying pathophysiology.

Purpose of the Study:

  • To review the clinical efficacy and safety of DMOADs for osteoarthritis.
  • To specifically evaluate glucosamine (GlcN) and pentosan polysulfate (PPS) as potential OA therapeutics.
  • To assess these agents based on European Medicines Agency outcome measures.

Main Methods:

  • Literature review of in vitro and experimental studies on GlcN and PPS.
  • Analysis of clinical trial data for efficacy and safety outcomes.
  • Evaluation against European Medicines Agency guidelines for OA treatments.

    • Main Results:

    • Preliminary studies suggest potential efficacy for GlcN and PPS in OA.
    • Further clinical data is needed to confirm therapeutic benefits and safety profiles.
    • Comparative effectiveness against NSAIDs and other DMOADs requires investigation.

    Conclusions:

    • Glucosamine and pentosan polysulfate show promise as novel OA treatments.
    • Rigorous clinical evaluation is essential to establish their role in OA management.
    • DMOADs represent a significant advancement in targeting OA's structural progression.